43200-83-5

Usage

Uses

Used in Pharmaceutical Industry:
3-((5-chloropyridin-2-yl)carbamoyl)pyrazine-2-carboxylic acid is used as an impurity in the production of Zopiclone (Z700500), a cyclopyrrolone derivative and a member of the non-benzodiazepine GABAA receptor agonists. It serves as a controlled substance (depressant) in the United States, but not in Canada. 3-((5-chloropyridin-2-yl)carbamoyl)pyrazine-2-carboxylic acid plays a role in the sedative and hypnotic effects of Zopiclone, which are utilized for the treatment of insomnia and other sleep disorders.
In the pharmaceutical industry, the presence of this impurity in Zopiclone is carefully monitored and controlled to ensure the safety and efficacy of the medication. 3-((5-chloropyridin-2-yl)carbamoyl)pyrazine-2-carboxylic acid's role in the sedative and hypnotic effects of Zopiclone highlights its importance in the development and production of non-benzodiazepine GABAA receptor agonists for the treatment of sleep disorders.

Upstream product

• 1072-98-6 5-chloro-2-pyridylamine 
• 4744-50-7 2,3-pyrazinedicarboxylic anhydride 

Downstream Products

• 43200-82-4 6-(5-chloro-2-pyridyl)-5,7-dioxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazine 
• 890052-06-9 N-{4-[(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]phenyl}-N'-(5-chloropyridin-2-yl)pyrazine-2,3-dicarboxamide 
• 138729-47-2 eszopiclone 
• 43200-80-2 zopiclon 
• 43200-81-3 6-(5-chloropyridin-2-yl)-7-hydroxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-one 
• 144025-93-4 eszopiclone dibenzoyl-D-tartrate 
• 144025-94-5 (R)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate D-(+)-O,O'-dibenzoyltartaric acid salt 

Relevant academic research and scientific papers

Process for the preparation of eszopiclone

The invention relates to a process for making of 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo-[3,4-b] pyrazin-5-yl-4-methyl piperazine-1-carboxylate, also known as zopiclone. The invention further describes an effective method for resolving of zopiclone into its enantiomers (eszopiclone and (R)-zopiclone) and also provides a method of recycling of (R)-zopiclone.

IMPROVED PROCESS FOR THE PREPARATION OF ZOPICLONE AND IT'S ENANTIOMERICALLY ENRICHED ISOMER

Present invention relates to an improved process for the preparation of Zopiclone and its enantiomerically enriched isomer (Eszopiclone). 6-(5-Chloropyridin-2- yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo [3,4-b] pyrazine is reacted with 1-chloro- carbonyl-4-methylpiperazine in the presence of alkali earth metal carbonates, hydroxides or oxides in a solvent medium to give Zopiclone. It is reacted with optically active acid in a mixture of water and water miscible organic solvent followed by work up to give Eszopiclone. The present invention also relates to process for the conversion of (R) or (S) Zopiclone to 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydro- pyrrolo- [3,4-b] - pyrazine of the intermediate which can be converted to racemic Zopiclone.

CYCLIC IMINOCARBAMATES AND USE THEREOF

The invention relates to novel cyclic iminocarbamates of formula (I), wherein R1, R2, R3, A, Z and n have the meaning cited in the description, to a method for the production thereof, to the use thereof for treating and/or for the prophylaxis of illnesses, and to the use thereof in the production of medicaments for treating and/or for the prophylaxis of diseases, in particular of thromboembolic diseases.

PYRAZINE DICARBOXAMIDES AND THE USE THEREOF

The invention relates to novel pyrazine dicarboxamides, methods for the use thereof, their use for treating and/or preventing diseases as well as to their use for producing medicaments for treating and/or preventing diseases, particularly thromboembolic disorders.